| Followers | 843 |
| Posts | 123024 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Friday, May 12, 2023 6:07:33 PM
https://finance.yahoo.com/news/aligos-therapeutics-announces-research-collaboration-210500298.html
Under the terms of the agreement, Aligos and Amoytop* will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights. Aligos will also receive an upfront payment and research collaboration funding and be eligible to receive up to a total of $109 million in development and sales milestone payments for licensed products as well as tiered royalties on net sales.
The up-front cash amount is presumably tiny since it wasn’t disclosed.
*Xiamen Amoytop Biotech Company Ltd.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent ALGS News
- Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 • GlobeNewswire Inc. • 05/27/2026 06:30:00 AM
- Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 • GlobeNewswire Inc. • 05/13/2026 06:05:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:08:02 PM
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/07/2026 08:05:00 PM
- Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 • GlobeNewswire Inc. • 04/30/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2026 08:33:53 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2026 08:29:42 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 08:25:49 PM
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/24/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:32:46 PM
- Aligos Therapeutics Jumps on China Licensing Agreement • IH Market News • 04/16/2026 02:22:44 PM
- Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection • GlobeNewswire Inc. • 04/16/2026 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/14/2026 08:17:32 PM
- Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation • GlobeNewswire Inc. • 04/14/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 08:14:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/05/2026 01:28:14 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2026 01:08:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:01:42 PM
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/05/2026 01:00:00 PM
- Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 • GlobeNewswire Inc. • 02/26/2026 01:00:00 PM
- Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 10:54:15 PM
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/30/2026 01:00:00 PM
- Aligos Therapeutics edges higher after update on Phase 2 HBV trial • IH Market News • 01/21/2026 03:47:22 PM
- Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates • GlobeNewswire Inc. • 01/21/2026 01:00:00 PM
